Articles
Retrospective on a century of genetics
The history of the International Congress of Genetics goes hand in hand with the history of genetics. [ + ]
Imaging apparatus characterises drops in 'dirty' laboratory environments
A high-fidelity spectrometric system for studying the behaviour of drops and particles in industrial flame reactors has been constructed by researchers at the University of Illinois at Urbana-Champaign
[ + ]Determining structure using NMR
A University at Buffalo chemist has developed a new, high-throughput method for obtaining nuclear magnetic resonance data that can potentially performing orders of magnitude faster than conventional methods
[ + ]The world is getting smaller for Australian nanotech ventures
As a nation, Australia has often lagged behind bigger and better-funded countries when it comes to seizing on a new technology and taking it to new places. But with the emerging nanotechnology industry, Australia is finding itself in a position of relative strength, despite our size. [ + ]
Mass spec and the soft cell
If mass spectrometry didn't exist, biologists would surely have had to invent it. Mass spectrometry has put the pep into peptide sequencing -- there's no quicker nor more accurate way of doing it. [ + ]
STEM CELL FEATURE PART 2: Tangled up in red?
For the second of our two-part series examining Australia's new laws on embryonic stem cell research and human cloning, Pete Young asked medical researchers, IVF clinics and companies developing stem cell-related products for their views on the impact of the legislation. [ + ]
Genomics: doing Moore with less
Genomics is experiencing its own manifestation of computing technology's Moore's law of cost and efficiency, says Prof Richard Gibbs: the volume of sequence data is increasing by around 10-fold every year as sequencing costs continue to plummet. [ + ]
STEM CELL FEATURE PART 1: Legislating the embryo
In the first part of a two-part series about Australia's new stem cell laws, Pete Young looks at the NHMRC's role and who will need to apply for a licence to do the research. [ + ]
The biotech report cards
As the new year begins, market analysts are sounding the same warnings that they did in 2002 -- that Australian biotechnology companies must consider strategies like mergers and acquisitions and alliances to survive. [ + ]
The future of drug delivery
The burgeoning area of drug delivery research could some day produce insulin pills for diabetics, laboratory-grown organs for transplants and plastic surgery, and an under-skin pharmacy on a microchip
[ + ]Quantitative analysis of small metal fragments by LA-ICP-MS
Small, irregularly shaped samples can present difficulties for the established methods of metal analysis. Laser-ablation ICP-MS offers accuracy and precision independent of sample form
[ + ]High-flying expat returns to give Monash the commercial edge
Roland Scollay has been an academic scientist, a commercial scientist, has held managerial positions in US biotechnology companies and most recently has been the CEO for a biotechnology start-up in the US. So it's a natural progression for him to return to the academic environment, this time to look for opportunities to commercialise academic research. [ + ]
Vacuum pump problems?
Are your vacuum pumps mysteriously breaking impellers, breaking or flogging keys, twisting shafts or prematurely trashing bearings? If so, the culprits could well be 'invisible' slugs of liquid and sludge
[ + ]Taxing moves in bioindustry
Australian bioindustry has a sweeping wish list of tax reform measures it desperately wants to see implemented. The trouble is, forcing through significant changes to the national tax structure has the same torturously long gestation period as developing a major new drug. [ + ]
INTERVIEW: The Andrews view: hang on for a big 2003
The biotech shake-up will intensify in 2003 but the horizon looks inviting on the far side of the wave of mergers expected to roll through the sector over the next 12 to 24 months. That's the view of Prof Peter Andrews, a leading member of the generation which has dramatically reshaped Australian bioscience in the last 15 years and a man who boasts a good track record in sculpting positive environments for young biotechs. [ + ]